Physician profile
Roza Liss
NPI 1235362781
$4,922.99
in general payments reported to CMS, 2019-2025
40 companies · $495 in 2025
The $495 reported for 2025 was more than what 75% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,061 · 2022: $1,156 · 2023: $1,229 · 2024: $982 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,705.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,344.23 | 2021-2025 | |
| Novo Nordisk INC | $657.56 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $291.39 | 2021-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals Lp | $248.39 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $241.39 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $166.14 | 2021-2023 | Xarelto |
| Amgen INC. | $157.68 | 2021-2025 | Evenity, Prolia, Prolia |
| Glaxosmithkline, LLC. | $136.56 | 2022-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $136.30 | 2021-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company Ltd. | $133.21 | 2022 | |
| Amarin Pharma, INC. | $127.22 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $124.84 | 2021 | |
| Inspire Medical Systems, INC. | $110.49 | 2023-2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $110.06 | 2021-2023 | Trintellix |
| Philips North America LLC | $97.91 | 2022-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roza Liss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.